专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090318511A1 SELECTIVE HYDROXAMATE BASED MMP INHIBITORS 有权
标题翻译：基于选择性羟基酸的MMP抑制剂
公开(公告)号：US20090318511A1
公开(公告)日：2009-12-24
申请号：US12295170
申请日：2007-03-27
申请人： Thomas Leutert , Jonathan E. Grob , Ruben Alberto Tommasi , Erin E. Pusateri , Ayako Honda
发明人： Thomas Leutert , Jonathan E. Grob , Ruben Alberto Tommasi , Erin E. Pusateri , Ayako Honda
IPC分类号： A61K31/44 , C07C311/15 , C07D213/56 , A61K31/18 , A61P35/00
CPC分类号： C07C311/19 , C07B2200/09 , C07C311/29 , C07C311/42 , C07C311/46 , C07C311/47 , C07D213/42 , C07D295/13
摘要： The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
摘要翻译：本发明提供式（I）化合物：所述化合物是MMP-9和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗以异常为特征的病症或疾病 MMP-9和/或MMP-12和/或MMP-13的活性。因此，式（I）化合物可用于治疗由MMP-9和/或MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供药物组合物。

2. 发明申请

US20120225882A1 SELECTIVE HYDROXAMATE BASED MMP INHIBITORS 有权
标题翻译：基于选择性羟基酸的MMP抑制剂
公开(公告)号：US20120225882A1
公开(公告)日：2012-09-06
申请号：US13469427
申请日：2012-05-11
申请人： Thomas Leutert , Jonathan E. Grob , Ruben Alberto Tommasi , Erin E. Pusateri , Ayako Honda
发明人： Thomas Leutert , Jonathan E. Grob , Ruben Alberto Tommasi , Erin E. Pusateri , Ayako Honda
IPC分类号： C07C311/37 , A61P11/00 , A61P19/02 , A61P9/10 , A61P35/00 , A61P1/16 , A61P13/12 , A61P29/00 , A61P9/04 , A61P25/00 , A61K31/4453 , A61K31/5375 , A61K31/495 , A61K31/4462 , A61P35/04 , A61P11/06
CPC分类号： C07C311/19 , C07B2200/09 , C07C311/29 , C07C311/42 , C07C311/46 , C07C311/47 , C07D213/42 , C07D295/13
摘要： The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
摘要翻译：本发明提供式（I）化合物：所述化合物是MMP-9和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗以异常为特征的病症或疾病 MMP-9和/或MMP-12和/或MMP-13的活性。因此，式（I）化合物可用于治疗由MMP-9和/或MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供药物组合物。

3. 发明授权

US08232427B2 Selective hydroxamate based MMP inhibitors 有权
公开(公告)号：US08232427B2
公开(公告)日：2012-07-31
申请号：US12295170
申请日：2007-03-27
申请人： Thomas Leutert , Jonathan E Grob , Ruben Alberto Tommasi , Erin E. Pusateri , Ayako Honda
发明人： Thomas Leutert , Jonathan E Grob , Ruben Alberto Tommasi , Erin E. Pusateri , Ayako Honda
IPC分类号： C07C303/00 , C07D211/70
CPC分类号： C07C311/19 , C07B2200/09 , C07C311/29 , C07C311/42 , C07C311/46 , C07C311/47 , C07D213/42 , C07D295/13
摘要： The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

4. 发明授权

US08314148B2 Selective hydroxamate based MMP inhibitors 有权
标题翻译：选择性羟肟酸基MMP抑制剂
公开(公告)号：US08314148B2
公开(公告)日：2012-11-20
申请号：US13469427
申请日：2012-05-11
申请人： Thomas Leutert , Jonathan E. Grob , Ruben Alberto Tommasi , Erin Keaney , Ayako Honda
发明人： Thomas Leutert , Jonathan E. Grob , Ruben Alberto Tommasi , Erin Keaney , Ayako Honda
IPC分类号： A01N41/06 , C07C303/00 , C07D211/70
CPC分类号： C07C311/19 , C07B2200/09 , C07C311/29 , C07C311/42 , C07C311/46 , C07C311/47 , C07D213/42 , C07D295/13
摘要： The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
摘要翻译：本发明提供式（I）化合物：所述化合物是MMP-9和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗以异常为特征的病症或疾病 MMP-9，和/或MMP-12和/或MMP-13的活性。因此，式（I）化合物可用于治疗由MMP-9和/或MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供药物组合物。

5. 发明授权

US4616002A Dihydro pyridine compounds, compositions and use 失效
标题翻译：二氢吡啶化合物，组成和用途
公开(公告)号：US4616002A
公开(公告)日：1986-10-07
申请号：US816461
申请日：1986-01-06
申请人： Bruno Kamber , Thomas Leutert , Hans Kuhnis , Kurt Eichenberger
发明人： Bruno Kamber , Thomas Leutert , Hans Kuhnis , Kurt Eichenberger
IPC分类号： C07D211/90 , C07D401/06 , C07D405/12 , C07D417/12 , C07K5/065 , A61K31/535 , A61K37/02 , C07D413/12 , C07K5/06
CPC分类号： C07D401/06 , C07D211/90 , C07D405/12 , C07D417/12 , C07K5/06078
摘要： Compounds of the formula I ##STR1## in which n represents 1, 2 or 3, Ar represents a carbocyclic or heterocyclic aryl radical, Ac represents the acyl radical of an acid, Z represents a radical --OR.sub.7 or --NR.sub.8 R.sub.9, R.sub.1 represents hydrogen, unsubstituted or substituted lower alkyl, a carbocyclic or heterocyclic aryl radical or free, etherified or esterified hydroxy, R.sub.2 and R.sub.3, independently of one another, each represents hydrogen, unsubstituted or substituted lower alkyl, formyl or functionally modified formyl, carboxy or functionally modified carboxy, a carbocyclic or heterocyclic aryl radical or unsubstituted or mono- or di-substituted amino, R.sub.4 represents hydrogen or lower alkyl, R.sub.5 and R.sub.6, independently of one another, each represents hydrogen, unsubstituted or substituted lower alkyl or a carbocyclic or heterocyclic aryl radical, R.sub.7, R.sub.8 and R.sub.9, independently of one another, each represents hydrogen, unsubstituted or substituted alkyl or a carbocyclic or heterocyclic aryl radical; in which R.sub.1 and R.sub.2 together or R.sub.1 and R.sub.3 together may represent unsubstituted or substituted lower alkylene in which a carbon atom is optionally replaced by a hetero atom, in which R.sub.4 and R.sub.5 together, and likewise R.sub.5 and R.sub.6 together and/or R.sub.8 and R.sub.9 together, independently of one another, may represent unsubstituted or substituted lower alkylene in which a carbon atom may have been replaced by a hetero atom, optical isomers of compounds of the formula I, mixtures of these optical isomers and salts of such compounds that have a salt-forming grouping, are distinguished by cardiovascular, especially blood pressure-reducing, properties. They are manufactured in a manner known per se.
摘要翻译：式I的化合物（I）其中n表示1,2或3，Ar表示碳环或杂环芳基，Ac表示酸的酰基，Z表示基团-OR7或-NR8R9，R1 代表氢，未取代或取代的低级烷基，碳环或杂环芳基或游离的醚化或酯化的羟基，R 2和R 3彼此独立地表示氢，未取代或取代的低级烷基，甲酰基或官能改性的甲酰基，羧基或官能改性的羧基，碳环或杂环芳基或未取代的或单取代或二取代的氨基，R 4表示氢或低级烷基，R 5和R 6彼此独立地表示氢，未取代或取代的低级烷基或碳环或杂环芳基，R 7，R 8和R 9彼此独立地表示氢，未取代或取代的烷基或碳环或杂环芳基; 其中R 1和R 2一起或R 1和R 3一起可以表示未取代或取代的低级亚烷基，其中碳原子任选被杂原子取代，其中R 4和R 5一起以及R 5和R 6一起和/或R 8和R 9 一起彼此独立地表示未取代或取代的低级亚烷基，其中碳原子可以被杂原子取代，式I化合物的光学异构体，这些光学异构体的混合物和这些化合物的盐，其具有盐形成分组由心血管特别是降血压特性区分。它们以本身已知的方式制造。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式